Pliant Therapeutics Inc (FRA:9PT)
€ 11.1 0.2 (1.83%) Market Cap: 662.91 Mil Enterprise Value: 264.58 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 27/100

Pliant Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 13, 2023 / 06:40PM GMT
Release Date Price: €26.4 (-0.75%)
Jeff Jones
Oppenheimer & Co. Inc. - Analyst

Good afternoon, everyone, and welcome to the Pliant Therapeutics fireside chat here at the Oppenheimer healthcare conference. I'm Jeff Jones. I'm a senior analyst here on the biotechnology team, and I'm thrilled to welcome the CEO, Bernard Coulie; and the Chief Medical Officer, Ãric Lefebvre.

Welcome, gentlemen. Thank you very much for taking the time to join us this afternoon.

Bernard Coulie
Pliant Therapeutics, Inc. - President & CEO

Thanks, Jeff.

Questions & Answers

Jeff Jones
Oppenheimer & Co. Inc. - Analyst

I guess, to start off, I start off with, for those who aren't familiar with the story, can you give us a quick overview of the company and in particular, your integrin-targeting technology platform?

Bernard Coulie
Pliant Therapeutics, Inc. - President & CEO

Absolutely. So at Pliant, we have been really focused for the past, I would say, six years on developing novel treatments for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot